Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health (NASDAQ:JAGX)/b) announced that founder, president and CEO Lisa Conte will present virtually at the on Wednesday, June 24, 2026 at 1:00 PM Eastern. Investors can register online, and a replay of the webcast will be available after the conference.
Jaguar Health (NASDAQ:JAGX) reported that stockholders approved all five proposals at the May 22, 2026 Annual Meeting, which was adjourned to June 8, 2026.
Founder, president & CEO Lisa Conte will present virtually at the Emerging Growth Conference on June 10, 2026.
Jaguar Health (NASDAQ:JAGX) highlighted how ethnobotanical research and sustainable harvesting of the Croton lechleri tree underpin development of crofelemer, an FDA-approved oral botanical drug for noninfectious diarrhea in adults with HIV/AIDS.
Crofelemer liquid and powder formulations are in development as adjunctive therapies for rare intestinal failure disorders MVID and SBS-IF, supported by a pivotal trial with extension phase, ESPGHAN 2026 presentations, proof-of-concept PS reductions up to 37% in MVID and 15% in SBS-IF, and complex CMC that may hinder generic replication.
Jaguar Health (NASDAQ:JAGX) reported that Nasdaq notified the company on May 26, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, and its securities remain listed and traded.
Q1 2026 net revenue increased 816% year-over-year and 527% sequentially, supported by a US out-license agreement with Future Pak for Mytesi and Canalevia-CA1. Jaguar is focusing on its pivotal-stage crofelemer program for rare intestinal failure, targeting an NDA in mid-2027 and seeking a development and commercialization partner.
Jaguar Health (NASDAQ:JAGX) reported strong Q1 2026 revenue growth driven by U.S. licensing of Mytesi and Canalevia-CA1 to Future Pak. Total net revenue rose 816% year over year to $20.3 million, with license and grant revenue of $19.1 million.
Income from operations reached $10.2 million versus a prior-year loss, while net loss to common shareholders narrowed to $7.0 million. Non-GAAP recurring EBITDA loss improved to $5.1 million. Jaguar is prioritizing crofelemer development for rare-disease intestinal failure indications.
Jaguar Health (NASDAQ:JAGX) announced an investor webcast on May 26, 2026 at 8:30 a.m. Eastern to review Q1 2026 financials and provide corporate updates. The company also plans to file its Form 10-Q for the quarter ended March 31, 2026 on May 20, 2026.
CEO Lisa Conte will present virtually at the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 at 10 a.m. Eastern. Replays of both events will be available online.
Jaguar Health (NASDAQ:JAGX) announced that the first pediatric patient with microvillus inclusion disease (MVID) has entered the active treatment only, single-blind extension phase of its pivotal multicenter randomized double-blind crossover trial of liquid oral crofelemer as adjunctive therapy to parenteral support.
The extension will assess longer-term safety and efficacy to support planned NDA filing in mid-2027, subject to study completion and regulatory alignment. The trial spans the US, EU, and UAE, and crofelemer has orphan drug designation from FDA and EMA for MVID.
Jaguar Health (NASDAQ:JAGX) regained compliance with Nasdaq's minimum 500,000 publicly held shares requirement after third-party investors exercised pre-funded warrants on May 4, 2026.
The Nasdaq Hearings Panel granted an extension of the company's deadline to meet the $1.00 bid price rule to May 18, 2026, during which Jaguar must evidence a closing bid of at least $1.00 for 10 consecutive business days.
Jaguar Health (NASDAQ:JAGX) family company Napo Pharmaceuticals held a preliminary FDA discussion to evaluate Breakthrough Therapy Designation for oral liquid crofelemer as adjunctive therapy to parenteral support (PS) for pediatric intestinal failure due to microvillus inclusion disease (MVID).
Crofelemer showed preliminary proof of concept in two open-label pediatric MVID patients with meaningful reductions in weekly PS needs; initial long-term results accepted for presentation at ESPGHAN 2026. A pivotal randomized placebo-controlled MVID trial has completed enrollment. Orphan designations granted in US and EU for MVID and short bowel syndrome.
Jaguar Health (NASDAQ:JAGX) announced Neonorm Dog, a plant-based, non-prescription extension of its Neonorm franchise to support normal stool formation, gut hydration, and bowel health in dogs. The franchise already includes Neonorm Foal and Neonorm Calf and uses a standardized botanical extract from Croton lechleri.
Neonorm Dog will be sold through select online and animal health retail channels after final packaging and labeling are completed; Jaguar highlights its animal health strategy and recent statistically significant topline trial results for crofelemer in dogs.